These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 25353650

  • 1. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
    Henderson JL, Kormos BL, Hayward MM, Coffman KJ, Jasti J, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, Chen Y, Needle E, Berger Z, Steyn SJ, Houle C, Hirst WD, Galatsis P.
    J Med Chem; 2015 Jan 08; 58(1):419-32. PubMed ID: 25353650
    [Abstract] [Full Text] [Related]

  • 2. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
    Estrada AA, Liu X, Baker-Glenn C, Beresford A, Burdick DJ, Chambers M, Chan BK, Chen H, Ding X, DiPasquale AG, Dominguez SL, Dotson J, Drummond J, Flagella M, Flynn S, Fuji R, Gill A, Gunzner-Toste J, Harris SF, Heffron TP, Kleinheinz T, Lee DW, Le Pichon CE, Lyssikatos JP, Medhurst AD, Moffat JG, Mukund S, Nash K, Scearce-Levie K, Sheng Z, Shore DG, Tran T, Trivedi N, Wang S, Zhang S, Zhang X, Zhao G, Zhu H, Sweeney ZK.
    J Med Chem; 2012 Nov 26; 55(22):9416-33. PubMed ID: 22985112
    [Abstract] [Full Text] [Related]

  • 3. Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.
    Ding X, Stasi LP, Ho MH, Zhao B, Wang H, Long K, Xu Q, Sang Y, Sun C, Hu H, Yu H, Wan Z, Wang L, Edge C, Liu Q, Li Y, Dong K, Guan X, Tattersall FD, Reith AD, Ren F.
    Bioorg Med Chem Lett; 2018 May 15; 28(9):1615-1620. PubMed ID: 29588215
    [Abstract] [Full Text] [Related]

  • 4. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H, Miller M, Poulet FM, Scott JD, Smith MD, Yin Z, Zhou X, Parker EM, Kennedy ME, Morrow JA.
    J Pharmacol Exp Ther; 2015 Dec 15; 355(3):397-409. PubMed ID: 26407721
    [Abstract] [Full Text] [Related]

  • 5. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
    Galatsis P, Henderson JL, Kormos BL, Han S, Kurumbail RG, Wager TT, Verhoest PR, Noell GS, Chen Y, Needle E, Berger Z, Steyn SJ, Houle C, Hirst WD.
    Bioorg Med Chem Lett; 2014 Sep 01; 24(17):4132-40. PubMed ID: 25113930
    [Abstract] [Full Text] [Related]

  • 6. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.
    Troxler T, Greenidge P, Zimmermann K, Desrayaud S, Drückes P, Schweizer T, Stauffer D, Rovelli G, Shimshek DR.
    Bioorg Med Chem Lett; 2013 Jul 15; 23(14):4085-90. PubMed ID: 23768909
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
    Gillardon F, Kremmer E, Froehlich T, Ueffing M, Hengerer B, Gloeckner CJ.
    J Neurosci Methods; 2013 Mar 30; 214(1):62-8. PubMed ID: 23318290
    [Abstract] [Full Text] [Related]

  • 13. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease.
    Koshibu K, van Asperen J, Gerets H, Garcia-Ladona J, Lorthioir O, Courade JP.
    Pharmacology; 2015 Mar 30; 96(5-6):240-7. PubMed ID: 26382237
    [Abstract] [Full Text] [Related]

  • 14. Triazolopyridazine LRRK2 kinase inhibitors.
    Franzini M, Ye XM, Adler M, Aubele DL, Garofalo AW, Gauby S, Goldbach E, Probst GD, Quinn KP, Santiago P, Sham HL, Tam D, Truong A, Ren Z.
    Bioorg Med Chem Lett; 2013 Apr 01; 23(7):1967-73. PubMed ID: 23454015
    [Abstract] [Full Text] [Related]

  • 15. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X, Choi HG, Buhrlage SJ, Gray NS.
    Expert Opin Ther Pat; 2012 Dec 01; 22(12):1415-26. PubMed ID: 23126385
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Novel cinnoline-based inhibitors of LRRK2 kinase activity.
    Garofalo AW, Adler M, Aubele DL, Bowers S, Franzini M, Goldbach E, Lorentzen C, Neitz RJ, Probst GD, Quinn KP, Santiago P, Sham HL, Tam D, Truong AP, Ye XM, Ren Z.
    Bioorg Med Chem Lett; 2013 Jan 01; 23(1):71-4. PubMed ID: 23219325
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.